1. Home
  2. CELC vs CBU Comparison

CELC vs CBU Comparison

Compare CELC & CBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • CBU
  • Stock Information
  • Founded
  • CELC 2011
  • CBU 1866
  • Country
  • CELC United States
  • CBU United States
  • Employees
  • CELC N/A
  • CBU N/A
  • Industry
  • CELC Medical Specialities
  • CBU Major Banks
  • Sector
  • CELC Health Care
  • CBU Finance
  • Exchange
  • CELC Nasdaq
  • CBU Nasdaq
  • Market Cap
  • CELC 3.1B
  • CBU 3.0B
  • IPO Year
  • CELC 2017
  • CBU N/A
  • Fundamental
  • Price
  • CELC $100.23
  • CBU $58.06
  • Analyst Decision
  • CELC Strong Buy
  • CBU Hold
  • Analyst Count
  • CELC 7
  • CBU 2
  • Target Price
  • CELC $95.29
  • CBU $68.00
  • AVG Volume (30 Days)
  • CELC 916.2K
  • CBU 231.7K
  • Earning Date
  • CELC 11-12-2025
  • CBU 10-21-2025
  • Dividend Yield
  • CELC N/A
  • CBU 3.28%
  • EPS Growth
  • CELC N/A
  • CBU 24.03
  • EPS
  • CELC N/A
  • CBU 3.88
  • Revenue
  • CELC N/A
  • CBU $776,264,000.00
  • Revenue This Year
  • CELC N/A
  • CBU $13.91
  • Revenue Next Year
  • CELC N/A
  • CBU $9.55
  • P/E Ratio
  • CELC N/A
  • CBU $14.77
  • Revenue Growth
  • CELC N/A
  • CBU 9.90
  • 52 Week Low
  • CELC $7.58
  • CBU $49.44
  • 52 Week High
  • CELC $103.06
  • CBU $71.41
  • Technical
  • Relative Strength Index (RSI)
  • CELC 78.25
  • CBU 57.24
  • Support Level
  • CELC $92.10
  • CBU $53.46
  • Resistance Level
  • CELC $103.06
  • CBU $58.84
  • Average True Range (ATR)
  • CELC 5.52
  • CBU 1.55
  • MACD
  • CELC 0.74
  • CBU 0.30
  • Stochastic Oscillator
  • CELC 90.84
  • CBU 84.02

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About CBU Community Bank System Inc.

Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.

Share on Social Networks: